We're thrilled to announce that Omic has reached profitability—a significant milestone for our bootstrapped company—and is accelerating investment in our platform and pipeline.

Sustainable Growth

Since launching our Digital Patient platform in 2020, we've seen strong demand from pharmaceutical partners:

  • 100+ Digital Patient models built for partner programs
  • 85% accuracy in predicting drug response in retrospective validation
  • 3 partnership agreements with pharmaceutical companies
  • Team growth from 6 to 10 employees

Revenue from these partnerships now exceeds our operating costs, allowing us to reinvest in growth while maintaining our independence.

Internal Pipeline Programs

We're using our profits to launch internal drug discovery programs in areas where our AI has identified compelling opportunities:

  • Oncology: Novel targets for treatment-resistant cancers
  • Metabolic disease: New approaches to diabetes and obesity
  • Autoimmune: Precision targets for inflammatory conditions

These programs will be fully internal, using our AI platform to drive every stage from target discovery through lead optimization.

Platform Expansion

We're also significantly expanding our platform capabilities:

  • Generative chemistry: AI systems that design novel drug molecules
  • Virtual clinical trials: Larger-scale simulation of clinical outcomes
  • Real-world evidence integration: Connecting Digital Patients to clinical outcomes data

Why Bootstrapped Works

Reaching profitability as a bootstrapped company validates our approach. We've proven that you can build serious drug discovery technology without venture funding—and that doing so creates better alignment with the long-term nature of pharmaceutical development.

Our partners appreciate working with a company that isn't under pressure to show hockey-stick growth or position for an exit. We're here to discover drugs, not flip a company.

Team Growth

We're hiring across all functions:

  • Computational biology and machine learning to advance our AI
  • Medicinal chemistry to support internal programs
  • Clinical development to plan for eventual human studies
  • Business development to expand partnerships

We expect to grow significantly over the next 18 months, funded by our growing partnership business.